桂林三金(002275) - 2022 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2022 reached ¥443,488,378.21, an increase of 18.03% year-over-year[7] - Net profit attributable to shareholders was ¥21,467,877.53, a decrease of 53.03% compared to the same period last year[7] - Net profit excluding non-recurring gains and losses was ¥14,655,019.81, up 97.43% year-over-year[7] - The company reported a basic earnings per share of ¥0.0281, a decrease of 64.61% compared to the same period last year[7] - The net profit attributable to shareholders of the listed company decreased by 53.03% to CNY 21,467,877.53 compared to the same period last year, primarily due to increased financial expenses and share-based payment provisions[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 97.43% to CNY 14,655,019.81, mainly due to the high non-recurring gains in the previous period from government subsidies[16] - The net profit for the current period is CNY 324,383,259.62, an increase from CNY 292,898,189.25 in the previous period, representing a growth of approximately 10.7%[33] - Operating profit for the current period is CNY 399,141,337.71, compared to CNY 361,237,488.69 in the previous period, indicating an increase of about 10.5%[33] - Total profit for the current period is CNY 395,977,951.32, up from CNY 361,468,249.37, reflecting a growth of approximately 9.5%[33] Assets and Liabilities - Total assets at the end of the period were ¥4,046,301,129.62, a decrease of 1.21% from the end of the previous year[7] - The total assets of the company were CNY 4,046,301,129.62, a decrease from CNY 4,095,868,127.50 at the beginning of the year[30] - The total liabilities amounted to CNY 1,115,823,550.33, down from CNY 1,256,050,962.24[30] - Shareholders' equity attributable to the parent company increased to ¥2,930,477,579.29, up 3.19% from the previous year[7] - The company's equity attributable to shareholders was CNY 2,930,477,579.29, an increase from CNY 2,839,817,165.26[30] Cash Flow - Cash flow from operating activities for the year-to-date was ¥245,023,811.12, down 15.94% year-over-year[7] - Cash received from operating activities decreased by 75.45% to CNY 44,575,648.45, mainly due to a reduction in government subsidies compared to the previous period[16] - Cash paid for purchasing goods and receiving services increased by 93.14% to CNY 418,554,988.76, driven by increased sales and production[16] - Cash received from investment activities increased by 143.56% to CNY 473,707,824.13, mainly due to a higher number of maturing equity instruments[16] - Cash paid for investment activities surged by 1,699.65% to CNY 802,864,785.84, primarily due to increased investments in equity instruments[16] - Net cash flow from operating activities was $245,023,811.12, a decrease of 15.98% compared to $291,495,282.61 in the previous period[41] - Total cash inflow from investment activities was $555,924,903.30, down from $628,619,639.60, reflecting a decrease of 11.56%[41] - Cash outflow from investment activities increased significantly to $974,123,558.30 from $254,862,021.01, indicating a rise of 282.73%[41] - Net cash flow from financing activities was -$175,223,838.83, an improvement from -$295,805,366.73 in the previous period[41] - Cash inflow from financing activities totaled $266,396,014.38, compared to $209,692,691.28 in the previous period, marking an increase of 27.00%[41] - Cash outflow for dividend distribution and interest payments was $333,588,479.24, up from $244,001,210.05, representing a rise of 36.67%[41] Expenses - Management expenses rose by 55.64% to CNY 169,949,093.70, primarily due to the timely recognition of share-based payments[16] - Financial expenses decreased by 63.89% to CNY -5,784,980.30, attributed to increased loan interest and changes in the company's financial structure[16] - Research and development expenses decreased to CNY 127,378,100.62 from CNY 169,712,734.98, a reduction of about 25%[33] - Sales expenses increased to CNY 350,494,315.37 from CNY 309,789,625.49, marking an increase of approximately 13.1%[33] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,010[19] - The largest shareholder, Guilin Sanjin Group Co., Ltd., holds 62.05% of the shares, totaling 364,586,500 shares[19] Other Information - The company received FDA approval for clinical trials of its subsidiary's drug, indicating potential future growth in the pharmaceutical sector[23] - The company plans to change the purpose of its remaining repurchased shares, totaling 2,631,400 shares, to be used for cancellation to reduce registered capital[24] - The company did not undergo an audit for the third quarter report[44] - Other comprehensive income after tax for the current period is CNY 13,020,354.41, compared to a loss of CNY 1,854,021.31 in the previous period[37] - Basic and diluted earnings per share for the current period are both CNY 0.5547, an increase from CNY 0.5091 in the previous period[37] - The tax expenses for the current period amounted to CNY 71,594,691.70, compared to CNY 68,570,060.12 in the previous period, reflecting an increase of approximately 3%[33]